[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products

Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III data forAlecensa(early-stage lung cancer) andOcrevus(subcutaneous injection; multiple sclerosis)Positive phase II data forzilebesiran(hypertension in patients at high risk of cardiovascular disease) and additional positive phase II data forfenebrutinib(multiple sclerosis)Positive longer-term efficacy and safety data forOcrevus(multiple sclerosis) andVabysmo (retinal vein occlusion, a severe eye disease)Launch of first validated test for earlierdiagnosis of neonatal sepsis and new module toimprove laboratory efficiencyOutlook for 2023 confirmedRoche CEO Thomas Schinecker: “We achieved good results in the first nine months of 2023, more than compensating for the expected decline in demand for COVID-19 products. Our Group sales excluding COVID-19 products continued to grow strongly by +9% at constant exchange rates. Additionally, we made significant progress...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news